Navigation Links
Echo Therapeutics Expands Into New Headquarters in Philadelphia
Date:5/5/2011

PHILADELPHIA, May 5, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced the relocation of its corporate headquarters from Franklin, MA to Philadelphia, PA.

The new office is located in the heart of Philadelphia's Center City Business District at 8 Penn Center.  Echo will continue to maintain and grow its Franklin office as its key operations hub where its engineering and product personnel are located.

"Since Echo Therapeutics' inception, the company has maintained its headquarters in Franklin where we have enjoyed a rewarding history of growth and success," stated Patrick Mooney, M.D., Echo's Chairman and CEO.  "The new headquarters responds directly to Echo's growing and evolving business and will accommodate both recent team expansion and additional hires planned for 2011 and beyond."

Echo operates at the following locations:

8 Penn Center, 1628 JFK Boulevard, Suite 300, Philadelphia, PA 19103 (Headquarters)

10 Forge Parkway, Franklin, MA 02038

About Echo TherapeuticsEcho Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals. For More Information:Patrick T. Mooney, M.D.

Media: Richard SternChairman and Chief Executive Officer

Stern &Co.(215) 717-4100

(212) 888-0044Connect With Us:- Visit our website at www.echotx.com

- Follow us on Twitter at www.twitter.com/echotx

- Join us on Facebook at www.facebook.com/echotx


'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
2. Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12
3. Amicus Therapeutics Announces First Quarter 2011 Financial Results and Continued Progress of Development Programs
4. Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide
5. Cell Therapeutics to Re-submit Pixantrone NDA in Consideration for Accelerated Approval in Accordance with Guidance from FDAs Office of New Drugs
6. Grifols and Talecris Biotherapeutics Announce the Signing of a Consent Agreement With FTC Staff
7. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
8. Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6
9. United Therapeutics Corporation Reports First Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. Announces Institutional Investors Purchase Approximately $16.0 Million of Preferred Stock and Warrants
11. Prime Therapeutics President and CEO Eric Elliott Delivers Speech at University of Minnesota College of Pharmacy Dialogues in Managed Care Leadership 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Inc. announced today that its fully owned USA ... York City Office in Yonkers, New York ... (TWO 2 ) homecare therapy. This new East Coast location has ... under the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. New ...
(Date:8/8/2017)... Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on ... the second quarter ended June 30, 2017. ... to date: Continued ... lead project, BL-8040: Announced plans to ... stem cell mobilization treatment for autologous bone-marrow transplantation in ...
(Date:8/7/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... president, effective Aug. 7, 2017. ... other interests and will serve as president emeritus during a ... us in multiple leadership roles since he joined Diplomat with ... has provided decisive, strategic leadership which continues to benefit our ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... August 22, 2017 , ... Although Labor Day is ... many communities have begun providing weekend displays, and numerous households celebrate the unofficial end ... can be downright terrifying for pets. , Kris Zambo, owner of Dynamite ...
(Date:8/21/2017)... ... August 22, 2017 , ... Nanoparticle research provides ... and safety. By learning and implementing best practices for containment using ventilated safety ... attendees will gain a better understanding of a method for safely testing nanotechnology ...
(Date:8/21/2017)... ... August 21, 2017 , ... Los Angeles area medical group ... academic year 2017-2018, Christina M. Busuito, M.D. and Lukasz Swistun, M.D. This one ... and Reconstructive Surgery. The candidate will have the opportunity to work with ...
(Date:8/21/2017)... ... August 21, 2017 , ... SportsEngine, Inc. , a ... Technology Partner of North Country Region Volleyball and will power registration, scheduling, and ... with providing sport management software to their member clubs. , SportsEngine ...
(Date:8/21/2017)... ... August 21, 2017 , ... ... place all over the country. , Outdoor running increases exposure to ultraviolet radiation, ... an increased risk of melanoma, and only half may be adequately protecting themselves ...
Breaking Medicine News(10 mins):